Arrhythmias & electrophysiology
Atrial fibrillation (AF) ablation using a novel “single-shot” map-and-ablate spherical array pulsed field ablation catheter: 1-Year outcomes of the first-in-human PULSE-EU trial
Authors' conclusion
The single-shot spherical array PFA catheter can safely achieve durable lesions, translating into good clinical efficacy.
Study context
- Population
- Patients with AF (paroxysmal 48%, persistent 52%)
- Participants
- 48 patients
- Outcome
- Acute PV isolation (PVI), PVI durability and atrial arrhythmia recurrence (primary and secondary efficacy end points)
Main finding
As reported in the abstract
Acute PVI
Pulmonary veins (PVs) acutely isolated
187 of 187 PVs
100%
Secondary outcomes
PV isolation (PVI) durability at invasive remapping · ∼3 months
- PVs durably isolated
- 158 of 169 PVs (93.5%)
- Remapping in 43/48 patients [89.5%]
Freedom from atrial arrhythmia (Kaplan-Meier estimate) · 1 year
- Paroxysmal AF
- 84.2%
- Persistent AF
- 80.0%
Acute lesion success, posterior wall and mitral isthmus
- Posterior walls
- 20 of 20 posterior walls (100%)
- Mitral isthmuses
- 10 of 11 mitral isthmuses (91%)
Safety
- Only complication: drug-responsive pericarditis
- 1
Original publication
AF ablation using a novel “single-shot” map-and-ablate spherical array pulsed field ablation catheter: 1-Year outcomes of the first-in-human PULSE-EU trial. Heart Rhythm. Published 18 May 2024. doi:10. 1016/ j. hrthm. 2024. 04. 102
Composed by AI from the published abstract and checked against it. How Briefs are made →